BIOGEN IDEC INC Form 8-K December 12, 2005

Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 6, 2005

Biogen Idec Inc.

(Exact name of registrant as specified in its charter)

Delaware0-1931133-0112644(State or other jurisdiction of incorporation)(Commission (I.R.S. Employer File Number)Identification No.)

14 Cambridge Center, Cambridge, Massachusetts

02142

(Address of principal executive offices)

(Zip Code)

Registrant s telephone number, including area code: (617) 679-2000

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

o Written

communications

pursuant to

Rule 425 under

the Securities

Act (17 CFR

230.425)

o Soliciting

material

pursuant to

Rule 14a-12

under the

Exchange Act

(17 CFR

240.14a-12)

o Pre-commencement

communications

pursuant to

Rule 14d-2(b)

under the Exchange

Act (17 CFR

240.14d-2(b))

o Pre-commencement

communications

pursuant to

Rule 13e-4(c)

under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

Item 1.01 Entry into a Material Definitive Agreement

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal

Officers.

Item 9.01 Financial Statements and Exhibits

SIGNATURES

EXHIBIT INDEX

Ex-99.1 Press Release, dated December 7, 2005

Table of Contents

Item 1.01 Entry into a Material Definitive Agreement

The Registrant is in discussion with William H. Rastetter, the Registrant s Executive Chairman, regarding severance arrangements.

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On December 7, 2005, the Registrant announced that William H. Rastetter, the Registrant s Executive Chairman, will retire from that position effective the end of the year. Dr. Rastetter is also resigning as a director of the Registrant effective the end of the year. Effective as of January 1, 2006, the Registrant s Chief Executive Officer, James C. Mullen, will assume Dr. Rastetter s executive duties. The Board has elected Bruce Ross, currently a director of the Registrant, as its non-executive Chairman of the Board effective as of January 1, 2006.

A copy of the press release announcing Dr. Rastetter s retirement is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(c) Exhibits.

99.1 Press Release issued by Biogen Idec Inc. dated December 7, 2005.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Biogen Idec Inc.

By: /s/ Raymond G. Arner Raymond G. Arner Acting General Counsel

Date: December 12, 2005

Table of Contents

EXHIBIT INDEX

Exhibit

Number Description of Exhibit

99.1 Press Release issued by Biogen Idec Inc. dated December 7, 2005.